48 Appendix 1, Regulation (EU) 2019/1390

In forcesince 31 Jul 2019
1.

The h-CLAT quantifies changes in the expression of cell surface markers associated with the process of activation of monocytes and dendritic cells (DC) (i.e. CD86 and CD54), in the human monocytic leukaemia cell line THP-1, following exposure to sensitisers (1)(2). The measured expression levels of CD86 and CD54 cell surface markers are then used for supporting the discrimination between skin sensitisers and non-sensitisers.

2.

The h-CLAT has been evaluated in a European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM)-coordinated validation study and subsequent independent peer review by the EURL ECVAM Scientific Advisory Committee (ESAC). Considering all available evidence and input from regulators and stakeholders, the h-CLAT was recommended by EURL ECVAM (3) to be used as part of an IATA to support the discrimination between sensitisers and non-sensitisers for the purpose of hazard classification and labelling. Examples of the use of h-CLAT data in combination with other information are reported in the literature (4)(5)(6)(7)(8)(9)(10)(11).

3.

The h-CLAT proved to be transferable to laboratories experienced in cell culture techniques and flow cytometry analysis. The level of reproducibility in predictions that can be expected from the test is in the order of 80 % within and between laboratories (3)(12). Results generated in the validation study (13) and other published studies (14) overall indicate that, compared with LLNA results, the accuracy in distinguishing skin sensitisers (i.e. UN GHS/CLP Cat.1) from non-sensitisers is 85 % (N=142) with a sensitivity of 93 % (94/101) and a specificity of 66 % (27/41) (based on a re-analysis by EURL ECVAM (12) considering all existing data and not considering negative results for chemicals with a Log Kow greater than 3.5 as described in paragraph 4). False negative predictions with the h-CLAT are more likely to concern chemicals showing a low to moderate skin sensitisation potency (i.e. UN GHS/CLP subcategory 1B) than chemicals showing a high skin sensitisation potency (i.e. UN GHS/CLP subcategory 1A) (4)(13)(15). Taken together, this information indicates the usefulness of the h-CLAT method to contribute to the identification of skin sensitisation hazards. However, the accuracy values given here for the h-CLAT as a stand-alone test are only indicative, since the test should be considered in combination with other sources of information in the context of an IATA and in accordance with the provisions of paragraphs 7 and 8 in the General introduction. Furthermore, when evaluating non-animal methods for skin sensitisation, it should be kept in mind that the LLNA test as well as other animal tests may not fully reflect the situation in humans.

4.

On the basis of the data currently available, the h-CLAT method was shown to be applicable to test chemicals covering a variety of organic functional groups, reaction mechanisms, skin sensitisation potency (as determined in in vivo studies) and physicochemical properties (3)(14)(15). The h-CLAT method is applicable to test chemicals soluble or that form a stable dispersion (i.e. a colloid or suspension in which the test chemical does not settle or separate from the solvent/vehicle into different phases) in an appropriate solvent/vehicle (see paragraph 14). Test chemicals with a Log Kow greater than 3.5 tend to produce false negative results (14). Therefore negative results with test chemicals with a Log Kow greater than 3.5 should not be considered. However, positive results obtained with test chemicals with a Log Kow greater than 3.5 could still be used to support the identification of the test chemical as a skin sensitiser. Furthermore, because of the limited metabolic capability of the cell line used (16) and because of the experimental conditions, pro-haptens (i.e. substances requiring enzymatic activation for example via P450 enzymes) and pre-haptens (i.e. substances activated by oxidation) in particular with a slow oxidation rate may also provide negative results in the h-CLAT (15). Fluorescent test chemicals can be assessed with the h-CLAT (17), nevertheless, strong fluorescent test chemicals emitting at the same wavelength as fluorescein isothiocyanate (FITC) or as propidium iodide (PI), will interfere with the flow cytometric detection and thus cannot be correctly evaluated using FITC-conjugated antibodies or PI. In such a case, other fluorochrome-tagged antibodies or other cytotoxicity markers, respectively, can be used as long as it can be shown they provide similar results as the FITC-tagged antibodies (see paragraph 24) or PI (see paragraph 18) e.g. by testing the proficiency substances in Appendix 1-2. In the light of the above, negative results should be interpreted in the context of the stated limitations and together with other information sources within the framework of IATA. In cases where there is evidence demonstrating the non-applicability of the h-CLAT method to other specific categories of test chemicals, it should not be used for those specific categories.

5.

As described above, the h-CLAT method supports the discrimination between skin sensitisers from non-sensitisers. However, it may also potentially contribute to the assessment of sensitising potency (4)(5)(9) when used in integrated approaches such as IATA. Nevertheless, further work, preferably based on human data, is required to determine how h-CLAT results may possibly inform potency assessment.

6.

Definitions are provided in Appendix 1.1.

7.

The h-CLAT method is an in vitro assay that quantifies changes of cell surface marker expression (i.e. CD86 and CD54) on a human monocytic leukemia cell line, THP-1 cells, following 24 hours exposure to the test chemical. These surface molecules are typical markers of monocytic THP-1 activation and may mimic DC activation, which plays a critical role in T-cell priming. The changes of surface marker expression are measured by flow cytometry following cell staining with fluorochrome-tagged antibodies. Cytotoxicity measurement is also conducted concurrently to assess whether upregulation of surface marker expression occurs at sub-cytotoxic concentrations. The relative fluorescence intensity of surface markers compared to solvent/vehicle control are calculated and used in the prediction model (see paragraph 26), to support the discrimination between sensitisers and non-sensitisers

8.

Prior to routine use of the test described in this Appendix to test method B.71, laboratories should demonstrate technical proficiency, using the 10 proficiency substances listed in Appendix 1.2. Moreover, test users should maintain an historical database of data generated with the reactivity checks (see paragraph 11) and with the positive and solvent/vehicle controls (see paragraphs 20-22), and use these data to confirm the reproducibility of the test in their laboratory is maintained over time.

9.

This test is based on the h-CLAT DataBase service on ALternative Methods to animal experimentation (DB-ALM) protocol no 158 (18) which represents the protocol used for the EURL ECVAM-coordinated validation study. It is recommended that this protocol is used when implementing and using the h-CLAT method in the laboratory. The following is a description of the main components and procedures for the h-CLAT method, which comprises two steps: dose finding assay and CD86/CD54 expression measurement.

10.

The human monocytic leukaemia cell line, THP-1, should be used for performing the h-CLAT method. It is recommended that cells (TIB-202™) are obtained from a well-qualified cell bank, such as the American Type Culture Collection.

11.

THP-1 cells are cultured, at 37oC under 5 % CO2 and humidified atmosphere, in RPMI-1640 medium supplemented with 10 % foetal bovine serum (FBS), 0,05 mM 2-mercaptoethanol, 100 units/ml penicillin and 100 μg/ml streptomycin. The use of penicillin and streptomycin in the culture medium can be avoided. However, in such a case users should verify that the absence of antibiotics in the culture medium has no impact on the results, for example by testing the proficiency substances listed in Appendix 1.2. In any case, in order to minimise the risk of contamination, good cell culture practices should be followed independently of the presence or not of antibiotics in the cell culture medium. THP-1 cells are routinely seeded every 2-3 days at the density of 0,1 to 0,2 × 106 cells/ml. They should be maintained at densities from 0,1 to 1,0 × 106 cells/ml. Prior to using them for testing, the cells should be qualified by conducting a reactivity check. The reactivity check of the cells should be performed using the positive controls, 2,4-dinitrochlorobenzene (DNCB) (CAS no 97-00-7, ≥ 99 % purity) and nickel sulfate (NiSO4) (CAS no 10101-97-0, ≥ 99 % purity) and the negative control, lactic acid (LA) (CAS no 50-21-5, ≥ 85 % purity), two weeks after thawing. Both DNCB and NiSO4 should produce a positive response of both CD86 and CD54 cell surface markers, and LA should produce a negative response of both CD86 and CD54 cell surface markers. Only the cells which passed the reactivity check are to be used for the assay. Cells can be propagated up to two months after thawing. Passage number should not exceed 30. The reactivity check should be performed according to the procedures described in paragraphs 20-24.

12.

For testing, THP-1 cells are seeded at a density of either 0,1 × 106 cells/ml or 0,2 × 106 cells/ml, and pre-cultured in culture flasks for 72 hours or for 48 hours, respectively. It is important that the cell density in the culture flask just after the pre-culture period be as consistent as possible in each experiment (by using one of the two pre-culture conditions described above), because the cell density in the culture flask just after pre-culture could affect the CD86/CD54 expression induced by allergens (19). On the day of testing, cells harvested from culture flask are resuspended with fresh culture medium at 2 × 106 cells/ml. Then, cells are distributed into a 24 well flat-bottom plate (500 μl, 1 × 106 cells/well) or a 96-well flat-bottom plate (80 μl, 1,6 × 105 cells/well).

13.

A dose finding assay is performed to determine the CV75, being the test chemical concentration that results in 75 % cell viability (CV) compared to the solvent/vehicle control. The CV75 value is used to determine the concentration of test chemicals for the CD86/CD54 expression measurement (see paragraphs 20-24).

14.

The test chemicals and control substances are prepared on the day of testing. For the h-CLAT method, test chemicals are dissolved or stably dispersed (see also paragraph 4) in saline or medium as first solvent/vehicle options or dimethyl sulfoxide (DMSO, 99 % purity) as a second solvent/vehicle option if the test chemical is not soluble or does not form a stable dispersion in the previous two solvents/vehicles, to final concentrations of 100 mg/ml (in saline or medium) or 500 mg/ml (in DMSO). Other solvents/vehicles than those described above may be used if sufficient scientific rationale is provided. Stability of the test chemical in the final solvent/vehicle should be taken into account.

15.

Starting from the 100 mg/ml (in saline or medium) or 500 mg/ml (in DMSO) stock solutions of the test chemicals, the following dilution steps should be taken:

For saline or medium as solvent/vehicle: Eight stock solutions (eight concentrations) are prepared, by two-fold serial dilutions using the corresponding solvent/vehicle. These stock solutions are then further diluted 50-fold into culture medium (working solutions). If the top final concentration in the plate of 1000 μg/ml is non-toxic, the maximum concentration should be re-determined by performing a new cytotoxicity test. The final concentration in the plate should not exceed 5000 μg/ml for test chemicals dissolved or stably dispersed in saline or medium.

For DMSO as solvent/vehicle: Eight stock solutions (eight concentrations) are prepared, by two-fold serial dilutions using the corresponding solvent/vehicle. These stock solutions are then further diluted 250-fold into culture medium (working solutions).The final concentration in plate should not exceed 1000 μg/ml even if this concentration is non-toxic.

The working solutions are finally used for exposure by adding an equal volume of working solution to the volume of THP-1 cell suspension in the plate (see also paragraph 17) to achieve a further two-fold dilution (usually, the final range of concentrations in the plate is 7,81–1000 μg/ml).

16.

The solvent/vehicle control used in the h-CLAT method is culture medium (for test chemicals solubilised or stably dispersed (see paragraph 4) either with medium or saline) or DMSO (for test chemicals solubilised or stably dispersed in DMSO) tested at a single final concentration in the plate of 0,2 %. It undergoes the same dilution as described for the working solutions in paragraph 15.

17.

The culture medium or working solutions described in paragraphs 15 and 16 are mixed 1:1 (v/v) with the cell suspensions prepared in the 24-well or 96-well flat-bottom plate (see paragraph 12). The treated plates are then incubated for 24±0.5 hours at 37oC under 5 % CO2. Care should be taken to avoid evaporation of volatile test chemicals and cross-contamination between wells by test chemicals, e.g. by sealing the plate prior to the incubation with the test chemicals (20).

18.

After 24±0.5 hours of exposure, cells are transferred into sample tubes and collected by centrifugation. The supernatants are discarded and the remaining cells are resuspended with 200 μl (in case of 96-well) or 600 μl (in case of 24-well) of a phosphate buffered saline containing 0,1 % bovine serum albumin (staining buffer). 200 μl of cell suspension is transferred into 96-well round-bottom plate (in case of 96-well) or micro tube (in case of 24-well) and washed twice with 200 μl (in case of 96-well) or 600 μl (in case of 24-well) of staining buffer. Finally, cells are resuspended in staining buffer (e.g. 400 μl) and PI solution (e.g. 20 μl) is added (for example, final concentration of PI is 0,625 μg/ml). Other cytotoxicity markers, such as 7-Aminoactinomycin D (7-AAD), Trypan blue or others may be used if the alternative stains can be shown to provide similar results as PI, for example by testing the proficiency substances in Appendix 1.2.

19.

The PI uptake is analysed using flow cytometry with the acquisition channel FL-3. A total of 10000 living cells (PI negative) are acquired. The cell viability can be calculated using the following equation by the cytometer analysis program. When the cell viability is low, up to 30000 cells including dead cells should be acquired. Alternatively, data can be acquired for one minute after the initiation of the analysis.

Cell viability

Number of living cells

Total Number of aquired cells

100

The CV75 value (see paragraph 13), i.e. a concentration showing 75 % of THP-1 cell survival (25 % cytotoxicity), is calculated by log-linear interpolation using the following equation:

Log CV75

75 c Logb75 a Logd

a c

Where:

a is the minimum value of cell viability over 75 %

c is the maximum value of cell viability below 75 %

b and d are the concentrations showing the value of cell viability a and c respectively

Other approaches to derive the CV75 can be used as long as it is demonstrated that this has no impact on the results (e.g. by testing the proficiency substances).

20.

The appropriate solvent/vehicle (saline, medium or DMSO; see paragraph 14) is used to dissolve or stably disperse the test chemicals. The test chemicals are first diluted to the concentration corresponding to 100-fold (for saline or medium) or 500-fold (for DMSO) of the 1.2 × CV75 determined in the dose finding assay (see paragraph 19). If the CV75 cannot be determined (i.e. if sufficient cytotoxicity is not observed in the dose finding assay), the highest soluble or stably dispersed concentration of test chemical prepared with each solvent/vehicle should be used as starting concentration. Please note that the final concentration in the plate should not exceed 5000 μg/ml (in case of saline or medium) or 1000 μg/ml (in case of DMSO). Then, 1.2-fold serial dilutions are made using the corresponding solvent/vehicle to obtain the stock solutions (eight concentrations ranging from 100×1.2 × CV75 to 100×0.335 × CV75 (for saline or medium) or from 500×1.2 × CV75 to 500×0.335 × CV75 (for DMSO)) to be tested in the h-CLAT method (see DB-ALM protocol NO. 158 for an example of dosing scheme). The stock solutions are then further diluted 50-fold (for saline or medium) or 250-fold (for DMSO) into the culture medium (working solutions). These working solutions are finally used for exposure with a further final two-fold dilution factor in the plate. If the results do not meet the acceptance criteria described in the paragraphs 29 and 30 regarding cell viability, the dose finding assay may be repeated to determine a more precise CV75. Please note that only 24-well plates can be used for CD86/CD54 expression measurement.

21.

The solvent/vehicle control is prepared as described in paragraph 16. The positive control used in the h-CLAT method is DNCB (see paragraph 11), for which stock solutions are prepared in DMSO and diluted as described for the stock solutions in paragraph 20. DNCB should be used as the positive control for CD86/CD54 expression measurement at a final single concentration in the plate (typically 4,0 μg/ml). To obtain a 4,0 μg/ml concentration of DNCB in the plate, a 2 mg/ml stock solution of DNCB in DMSO is prepared and further diluted 250-fold with culture medium to a 8 μg/ml working solution. Alternatively, the CV75 of DNCB, which is determined in each test facility, could be also used as the positive control concentration. Other suitable positive controls may be used if historical data are available to derive comparable run acceptance criteria. For positive controls, the final single concentration in the plate should not exceed 5000 μg/ml (in case of saline or medium) or 1000 μg/ml (in case of DMSO). The run acceptance criteria are the same as those described for the test chemical (see paragraph 29), except for the last acceptance criterion since the positive control is tested at a single concentration.

22.

For each test chemical and control substance, one experiment is needed to obtain a prediction. Each experiment consists of at least two independent runs for CD86/CD54 expression measurement (see paragraphs 26-28). Each independent run is performed on a different day or on the same day provided that for each run: a) independent fresh stock solutions and working solutions of the test chemical and antibody solutions are prepared and b) independently harvested cells are used (i.e. cells are collected from different culture flasks); however, cells may come from the same passage. Test chemicals and control substances prepared as working solutions (500 μl) are mixed with 500 μl of suspended cells (1x106 cells) at 1:1 ratio, and cells are incubated for 24±0.5 hours as described in paragraphs 20 and 21. In each run, a single replicate for each concentration of the test chemical and control substance is sufficient because a prediction is obtained from at least two independent runs.

23.

After 24±0.5 hours of exposure, cells are transferred from 24 well plate into sample tubes, collected by centrifugation and then washed twice with 1ml of staining buffer (if necessary, additional washing steps may be done). After washing, cells are blocked with 600 μl of blocking solution (staining buffer containing 0,01 % (w/v) globulin (Cohn fraction II, III, human; SIGMA, #G2388-10G or equivalent)) and incubated at 4oC for 15 min. After blocking, cells are split in three aliquots of 180 μl into a 96-well round-bottom plate or micro tube.

24.

After centrifugation, cells are stained with 50 μl of FITC-labelled anti-CD86, anti-CD54 or mouse IgG1 (isotype) antibodies at 4oC for 30 min. The antibodies described in the h-CLAT DB-ALM protocol no 158 (18) should be used by diluting 3:25 v/v (for CD86 (BD-PharMingen, #555657; Clone: Fun-1)) or 3:50 v/v (for CD54 (DAKO, #F7143; Clone: 6.5B5) and IgG1 (DAKO, #X0927)) with staining buffer. These antibody dilution factors were defined bythe test developers as those providing the best signal-to-noise ratio. Based on the experience of the test developers, the fluorescence intensity of the antibodies is usually consistent between different lots. However, users may consider titrating the antibodies in their own laboratory's conditions to define the best concentrations for use. Other fluorochrome-tagged anti-CD86 and/or anti-CD54 antibodies may be used if they can be shown to provide similar results as FITC-conjugated antibodies, for example by testing the proficiency substances in Appendix 1.2. It should be noted that changing the clone or supplier of the antibodies as described in the h-CLAT DB-ALM protocol no 158 (18) may affect the results. After washing twice or more with 150 μl of staining buffer, cells are resuspended in staining buffer (e.g. 400 μl), and the PI solution (e.g. 20 μl to obtain a final concentration of 0,625 μg/ml) or another cytotoxicity marker's solution (see paragraph 18) is added. The expression levels of CD86 and CD54, and cell viability are analysed using flow cytometry.

25.

The expression of CD86 and CD54 is analysed with flow cytometry with the acquisition channel FL-1. Based on the geometric mean fluorescence intensity (MFI), the relative fluorescence intensity (RFI) of CD86 and CD54 for positive control (ctrl) cells and chemical-treated cells are calculated according to the following equation:

RFI

MFI of chemical–treated cell MFI of chemical–treated isotype control cells

MFI of solventvehicle–treated ctrl cells MFI of solventvehicle–treated isotype ctrl cells

100

The cell viability from the isotype control (ctrl) cells (which are stained with mouse IgG1 (isotype) antibodies) is also calculated according to the equation described in paragraph 19.

26.

For CD86/CD54 expression measurement, each test chemical is tested in at least two independent runs to derive a single prediction (POSITIVE or NEGATIVE). An h-CLAT prediction is considered POSITIVE if at least one of the following conditions is met in 2 of 2 or in at least 2 of 3 independent runs, otherwise the h-CLAT prediction is considered NEGATIVE (Figure 1):

The RFI of CD86 is equal to or greater than 150 % at any tested concentration (with cell viability ≥ 50 %);

The RFI of CD54 is equal to or greater than 200 % at any tested concentration (with cell viability ≥ 50 %).

This article is long: the rest is at the official publication.